12,372 trials
Asthma
Primary: Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period…
Primary Insomnia
Primary: Suvorexant HD Versus Placebo: Change From Baseline in Mean Subjective Total Sleep Time (sTSTm) at Month 1 — 48.7; 22.4 minutes — p=<0.00001
Adult Attention Deficit Hyperactivity Disorder · Cocaine Dependence
Primary: Last Three Weeks of Cocaine Abstinence Based on Urine Toxicology Results and Self Reported Use — 7; 18; 30 percentage of participants
Primary Insomnia
Primary: Suvorexant HD Versus Placebo: Change From Baseline in Mean Subjective Total Sleep Time (sTSTm) at Month 1 — 42.6; 23.1 minutes — p=<0.00001
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — 8.08; 7.58; 0.03; -0.47 percent of HbA1c in blood — p=<0.001
Marfan Syndrome
Primary: Aortic Biophysical Properties - Pulse Wave Velocity — -1.15; -0.22 change in meters/second
Alcohol Consumption
Primary: Reduction in Percentage of Heavy Drinking Days — 14.0; 11.0 percentage of heavy drinking days
Migraines
Primary: Percentage of Participants Reporting Pain Freedom at 2 Hours Post-dose (First Migraine Attack) — 21.9; 25.1; 10.2 Percentage of participants — p=<0.001
Trocar Slippage
Primary: Trocar Slippages With LaproStop — 1; 2; 3 Participants
Insomnia
Primary: Percentage of Participants Who Experienced Cataplexy Adverse Events (AEs) During the Double-Blind (DB) Treatment Phase — 0.0; 0.0 percentage of participants
Severe Hemophilia A
Primary: Incidence Rate of FVIII Inhibitor Development — 0; 0; 0; 0 percentage of participants
Fibromyalgia · Neurocognition
Primary: Visual Analogue Scale for Pain — 59.4; 68.6; 58.5; 66.2 mm
Anemia · Hematologic Diseases · Cardiovascular Diseases
Primary: Inability to Walk 10 Feet or Across a Room Without Human Assistance or Death — 351; 347 participants
Myocardial Infarction · Unstable Angina · Coronary Artery Disease
Primary: Hemoglobin Concentration — 10.30; 9.03; 10.78; 8.98 g/dL — p=<0.001
Epilepsy
Primary: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) — 7 Participants